NCT06007677 - A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

March 31, 2031

Study Completion Date

March 31, 2031

Conditions

Hereditary Angioedema

Interventions

DRUG

STAR-0215

STAR-0215 will be administered as a subcutaneous injection.

Trial Locations (22)

1680

Diagnostic Consultative Center Convex Ltd., Sofia

12203

Charité Universitätsmedizin Berlin, Berlin

17033

Penn State Health Milton S. Hershey Medical Center, Hershey

20815

Institute for Asthma and Allergy, PC, Chevy Chase

35209

Allervie Clinical Research, Birmingham

43235

Optimed Research, Columbus

60596

Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt

63110

Washington University School of Medicine, St Louis

72205

Acuro Research, Little Rock

75231

AARA Research Center, Dallas

85251

Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD, Scottsdale

89075

Universitätsklinikum Ulm, Ulm

90404

Raffi Tachdjian MD, Inc, Santa Monica

92122

UC San Diego US HAEA Angioedema Center, San Diego

94598

Allergy & Asthma Clinical Research, Walnut Creek

02114

Massachusetts General Hospital, Boston

T6G 2R3

University of Alberta, Edmonton

K1H 1E4

Ottawa Allergy Research Corporation, Ottawa

550 05

Institute of Clinical Immunology/Allergology, Faculty Hospital, Hradec Kralove, Hradec Králové

31-503

Szpital Uniwersytecki w Krakowie, Krakow

CB2 0QQ

Addenbrooke's Hospital, Cambridge

LS9 7TF

St. James's Hospital, Leeds